Improvement of Lipid and Glucose Metabolism by Capsiate in Palmitic

Subscriber access provided by Kaohsiung Medical University

Bioactive Constituents, Metabolites, and Functions

Improvement of Lipid and Glucose Metabolism by Capsiate in Palmitic Acid-Treated HepG2 Cells via Activation of AMPK/SIRT1 Signal Pathway Yufan Zang, Li Fan, Jihua Chen, Ruixue Huang, and Hong Qin J. Agric. Food Chem., Just Accepted Manuscript • DOI: 10.1021/acs.jafc.8b01831 • Publication Date (Web): 10 Jun 2018 Downloaded from http://pubs.acs.org on June 10, 2018

Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

Page 1 of 42

Journal of Agricultural and Food Chemistry

1

Improvement of Lipid and Glucose Metabolism by Capsiate in

2

Palmitic Acid-Treated HepG2 Cells via Activation of

3

AMPK/SIRT1 Signal Pathway

4

Yufan Zang1,†, Li Fan1,†, Jihua Chen1, Ruixue Huang2, Hong Qin1,*

5

1 Department of Nutrition Science and Food Hygiene, Xiangya School of

6

Public Health, Central South University, 110 Xiangya Road, Changsha, Hunan

7

Province, China, 410078

8

2 Department of Occupational and Environmental Health, Xiangya School of

9

Public Health, Central South University, 110 Xiangya Road, Changsha, Hunan

10

Province, China, 410078

11

*Corresponding author: Hong Qin, Tel: + 86 15974222668, E-mail:

12

[email protected], Fax: + 86 0731 84805454.

13

†These two authors contributed equally to this work.

1

ACS Paragon Plus Environment


14

Abstract：Capsiate, a non-pungent ingredient of CH-19 Sweet, exhibits

15

anti-obesity effects on animals and humans. This study investigated the effects

16

and molecular mechanism of capsiate on lipid and glucose metabolism in

17

PA-treated HepG2 cells. Results showed that compared with the PA-alone

18

group, 100 μM capsiate inhibited lipid accumulation, decreased TG (0.0562±

19

0.0142 vs 0.0381±0.0055 mmol/gprot, P = 0.024) and TC (0.1087±0.0037 vs

20

0.0359±0.0059 mmol/gprot, P = 0.000) levels, while increased HDL-C level

21

(0.0189±0.0067 vs 0.1050±0.0106 mmol/gprot, P = 0.000) and glycogen

22

content (0.0065±0.0007 vs 0.0146±0.0008 mg/106 cells, P = 0.000) of

23

PA-treated HepG2 cells. 100 μM Capsiate also up regulated the level of CD36

24

(P = 0.000), phosphorylation of ACC (P = 0.034) and expression of CPT1 (P =

25

0.013) in PA-treated HepG2 cells, leading to a positive enhancement of lipid

26

metabolism. Meanwhile, 100 μM capsiate up regulated the levels of GLUT1,

27

GLUT4, GK and phosphorylation of GS (P = 0.001, 0.029, 0.000, 0.045,

28

respectively), down regulated PEPCK level (P = 0.001) to improve glucose

29

metabolism in PA-treated HepG2 cells. Furthermore, the phosphorylation of

30

AMPK and expression of SIRT1 in HepG2 cells were increased by 100 μM

31

capsiate treatment (P = 0.001 and 0.000, respectively), while FGF21 level was

32

decreased (P = 0.003). Most of these effects were reversed by pre-treatment

33

with compound C, a selective AMPK inhibitor. Thus, capsiate might improve

34

lipid and glucose metabolism in HepG2 cells by activating AMPK/SIRT1

35

signaling pathway.

2


Page 2 of 42

Page 3 of 42


36

Keywords: Capsiate; obesity; high fat; lipid metabolism; glucose metabolism

37

INTRODUCTION

38

Obesity is always accompanied by lipid and glucose metabolic disorders,

39

and is a major cause for the development of hyperlipidemia and non-alcoholic

40

fatty liver disease (NAFLD)1. As liver plays a key role in energy metabolism,

41

extensive efforts have been focused on the treatment of the hepatic lipid and

42

glucose metabolic disorders associated with obesity. Currently, although

43

several therapeutic agents of NAFLD have been assessed, there are no

44

pharmacotherapies specifically approved for NAFLD management2, 3. Hence,

45

finding novel phytochemicals that extracted from normal food, which could

46

target both the hepatic lipid as well as glucose metabolism disorder, is of

47

significant interest.

48

Recently, health benefits associated with the consumption of capsiate,

49

which is extracted from sweet pepper Capsicum CH-194, have been well

50

reported. It has been demonstrated that capsiate could relieve inflammation5

51

and attenuate insulin resistance 6, both of which are metabolic disorders

52

associated with obesity. Currently, capsiate has been shown to serve as

53

promising therapies for obesity, such as promoting white fat “browning” and

54

stimulating energy consumption7-10. In addition, our previous study and some

55

other studies suggested that capsiate could improve lipid metabolism and

56

promote the use of glucose in liver of obese rodents 6, 11, 12. Some of these

3



57

studies demonstrated that the metabolic homeostasis effect of capsiate partly

58

dependent on the activation of transient receptor potential vanilloid subtype 1

59

(TRPV1) receptor7, 9. However, specific mechanisms of capsiate remain largely

60

unexplored. In view of the multiple physiological effects, we supposed that

61

capsiate could relieve lipid and glucose metabolic disorders of NAFLD via

62

more complicated signaling pathways other than TRPV1. It is accepted that the activation of adenosine monophosphate-activated

63 64

protein kinase (AMPK), the energy sensor protein, is an important step in

65

reducing lipid accumulation in liver13. Once activated, AMPK modulates

66

hepatic energy metabolism by multiple mechanisms such as enhancing fatty

67

acid oxidation, inhibiting lipid synthesis as well as repressing

68

gluconeogenesis14. Sirtuin 1 (SIRT1) is another key regulator, which involved

69

in hepatic lipid and glucose metabolic homeostasis by stimulating various

70

downstream signaling proteins15. In this regard, finding some phytochemical to

71

activate AMPK and SIRT1 is a sensible strategy in the treatment of NAFLD 16,

72

17

73

. The present study was the first to examine if capsiate could regulate the

74

hepatic lipid and glucose metabolism simultaneously under high fat

75

environment in vitro. We also sought to ascertain the exact mechanism of

76

capsiate on energy metabolism. The major findings of this study were that

77

capsiate reduced lipid accumulation and increased glycogen synthesis of

4


Page 4 of 42

Page 5 of 42


78

HepG2 cells that treated with palmitic acid (PA), and the AMPK/SIRT1

79

signaling pathway was critical for these observed effects.

80

MATERIALS AND METHODS

81

Chemicals. Capsiate (97.3 % pure) was purchased from Sigma-Aldrich (St.

82

Louis, MO, USA). PA was purchased from Regent Science (Shenzhen, China).

83

HepG2 cells were purchased from Peking Union Cell Center (Beijing, China).

84

Oil red O was purchased from Solarbio Science & Technology Co., Ltd.

85

(Beijing, China). Triglyceride (TG), total cholesterol (TC), high-density

86

lipoprotein cholesterol (HDL-C) and glycogen assay kits were purchased from

87

Jiancheng Bioengineering Institute (Nanjing, China). MTT assay kit and the

88

Goat anti-Rabbit IgG antibody combined with horseradish peroxidase were

89

purchased from Ding Guo Changsheng Biotechnology Co., Ltd. (Beijing,

90

China). Antibodies against cluster of differentiation 36 (CD36, #A1470),

91

carnitine palmityl transferase 1 (CPT1, #A5037), glucose transporter 1 (GLUT1,

92

#A6982), glucose transporter 2 (GLUT2, #A9843), glucose transporter 4

93

(GLUT4, #A7637), glucokinase (GK, #A6293), phosphoenolpyruvate

94

carboxykinase (PEPCK, #A4005), SIRT1 (#A0230) and β-actin (#AC026) were

95

purchased from ABclonal (Boston, MA, USA). Antibodies against acetyl CoA

96

Carboxylase (ACC, #3676), phospho-Acetyl-CoA Carboxylase (p-ACC,

97

#11818), AMPKα (#5831) and phospho-AMPKα (p-AMPKα, #2535) were

98

purchased from Cell Signaling Technology, Inc . (Boston, MA, USA). Antibodies

5



99

against glycogen synthase (GS, #ab40810), phospho-GS (p-GS, #ab81230)

100

and fibroblast growth factor 21 (FGF21, #ab171941) were purchased from

101

Abcam Inc. (Cambridge, UK). Compound C was purchased from MCE (NJ,

102

USA).

103

PA Preparation. PA was prepared according to the method previously

104

described by Qin et al18. Briefly, PA was dissolved in 100mM NaOH solution at

105

70 ℃, and mixed with 10% (w/v) fatty acid-free bovine serum albumin (BSA)

106

at 55 ℃. The concentration of the stock PA solution was 5 mM. Then the liquid

107

was membrane-filtered and diluted 1:20 (v/v) with Dulbecco’s modified Eagle’s

108

medium (DMEM) to obtain 0.25 mM PA.

109

Cell Culture. HepG2 cells were cultured in 4.5 g/L glucose DMEM with 10%

110

(v/v) fetal bovine serum (FBS) and 1% Penicillin-Streptomycin Solution (100

111

U/mL penicillin and 100 μg/mL streptomycin). After reaching 80% confluence,

112

the cells were treated with or without 0.25mM PA for 24h. Then the cells which

113

exposed to PA were treated with capsiate at different concentrations (0, 25, 50,

114

and 100 μM) for 24h. In the experiments with the AMPK inhibitors, HepG2 cells

115

were pre-treated with 10 μM compound C for 1 h prior to capsiate treatment.

116

MTT Assay. MTT assay was used to measure cell viability. HepG2 cells were

117

seeded at a density of 6.0 × 103 cells/well in 96-well plates and cultured

118

overnight. Then cells were treated with different concentrations of PA (0, 0.125,

119

0.25, 0.5 and 1.0 mM) for 48 h, or different concentrations of capsiate (0, 12.5,

120

25, 50, 100, 200 and 400 μM) for 24 h. For further studies, HepG2 cells were

6


Page 6 of 42

Page 7 of 42


121

also treated with 0.25 mM PA for 24h and then co-incubated with different

122

concentrations of capsiate (0, 12.5, 25, 50, 100, 200 and 400 μM) for an

123

additional 24 h. And then, 20 μL of MTT solution was added to each well for 4 h

124

at 37 ℃. Next, the supernatants was removed, the formazan crystals were

125

dissolved in 150 μL DMSO. The absorbance values were measured at 570 nm

126

by a microplate reader (Power Wave XS2; BioTek Instruments, Inc., VT).

127

Lipid Content Assays. Lipid accumulation was detected by oil red O staining

128

which performed according to a slightly modified method previously described

129

by Weston et al19: after fixing in 4% paraformaldehyde for 30 min, the cells

130

were washed in PBS and then stained with freshly prepared oil red O for 30

131

min, following rinsing with 60% isopropanol and distilled water. Subsequently,

132

the lipid droplets were observed under an inverted microscope. The contents

133

of TG and TC were detected by GPO-PAP method, and the content of HDL-C

134

was measured by double reagent method using commercially available kits.

135

The content of each index was measured by a microplate reader and

136

expressed as mmol / gprot.

137

Glycogen Content Assay. Each group of cells was counted, and then the

138

glycogen content of HepG2 cells was detected by anthrone-sulfuric acid

139

method using a glycogen assay kit. Briefly, HepG2 cells were digested and

140

centrifuged at 156 ×g for 10 min, and the precipitates were transferred to

141

glass tubes with 0.225 mL alkaline liquor. Samples were incubated in boiling

142

water for 20 min, and then 0.1 mL hydrolyzate was diluted by distilled water

7



143

and 2 mL color-substrate solution, according to the instruction. Subsequently,

144

samples were incubated in boiling water for 5 min. Thereafter, the OD value of

145

each group was determined at 620 nm by an ultra-micro spectrophotometer

146

(Implen GmbH, Schatzbogen, Germany). The cell total glycogen content was

147

calculated and expressed as mg /106 cells.

148

Western Blot Analysis. The cells were lysed in RIPA buffer and centrifuged at

149

14000 ×g for 12 min to obtain the supernatant. Then the total protein content

150

of each group was measured by an ultra-micro spectrophotometer.

151

Subsequently, volumes of extracted protein samples were calculated

152

according to 40 μg per group, and then the samples were separated by

153

SDS-PAGE and transferred 2 h to polyvinylidene difluoride (PVDF)

154

membranes. Especially, ACC and p-ACC were transferred 5 h to PVDF

155

membranes. After blocking with 5% skim milk powder or 3% BSA in TBST, the

156

membranes were incubated with ACC (1:1000), p-ACC (1:1000), CPT1

157

(1:1000), CD36 (1:1000), GLUT1 (1:1000), GLUT2 (1:1000), GLUT4 (1:1000),

158

GK (1:1000), PEPCK (1:1000), GS (1:10000), p-GS (1:10000), AMPKα

159

(1:1000), p-AMPKα (1:1000), SIRT1 (1:1000) or FGF21 (1:1000) primary

160

antibodies overnight at 4 ℃. And β-actin (1:300000) was used as a reference

161

protein. After being washed in TBST, the membranes were incubated with the

162

goat anti-rabbit IgG antibody (1:6000, Ding Guo Changsheng Biotechnology

163

Co., Ltd., Beijing, China) for 1 h at room temperature. Protein bands were

164

detected using the chemiluminescence imager (Tanon-5500, Tanon Science &

8


Page 8 of 42

Page 9 of 42


165

Technology Co., Ltd. Shanghai, China) and the intensities were assessed by

166

Autogel software. The expression levels of proteins were analyzed by

167

semi-quantitative method.

168

Statistical Analysis. All analyses were done with SPSS 18.0 software (SPSS

169

Inc., Chicago, IL, USA). The data were shown as means ± SD (n = 3).

170

Differences among groups were calculated by one-way analysis of variance

171

(ANOVA) and LSD post-hoc test (more than two groups), or independent

172

samples t-test (two groups). P < 0.05 was considered to indicate a statistically

173

significantly difference.

174

RESULTS

175

Effects of PA and Capsiate on HepG2 Cell Viability. For cellular toxicity,

176

the MTT assay was performed to ensure that treatment with PA and capsiate

177

did not affect cellular viability. Neither the treatment with 0.25 mM of PA for 48

178

h nor the treatment with 0–400 μM of capsiate for 24 h inhibited the growth of

179

HepG2 cells (Fig. 1A, 1B). In addition, the viability of HepG2 cells which

180

exposed to PA did not be reduced after treatment with 0–100 μM of capsiate,

181

but it could be affected after treatment with 200 and 400 μM of capsiate (Fig.

182

1C). Based on these results, 25, 50 and 100 μM of capsiate were selected for

183

our experiments.

184

Effects of Capsiate on Lipid Accumulation in PA-Treated HepG2

185

Cells. Treatment with 0.25 mM PA led to a dramatic increase of lipid droplets in

9



186

HepG2 cells compared with the normal control group (Fig. 2A, 2B). After

187

treating with capsiate, the cells contained significantly less lipid droplets (Fig.

188

2C, 2D, 2E). The result indicated that capsiate could effectively reduce the lipid

189

accumulation in PA-treated HepG2 cells.

190

Effects of Capsiate on TG, TC and HDL-C Contents in PA-Treated

191

HepG2 Cells. Compared with the control group, the TG and TC contents were

192

significantly increased (0.0246±0.0045 mmol/gprot vs 0.0562±0.0142

193

mmol/gprot, P = 0.001 and 0.0086±0.0049 mmol/gprot vs 0.1087±0.0037

194

mmol/gprot, P = 0.000, respectively) in 0.25 mM PA-treated HepG2 cells. To

195

verify the improvement effect of capsiate on lipid metabolism, the cells which

196

exposed to PA were treated with capsiate at different concentrations. Results

197

showed that compared with the PA-alone group, capsiate effectively

198

decreased TG (0.0506±0.0043, 0.0452±0.0087, 0.0381±0.0055 mmol/gprot

199

at 25 μM, 50 μM and 100 μM, respectively) and TC (0.0741±0.0064, 0.0255

200

±0.0042, 0.0359±0.0059 mmol/gprot at 25 μM, 50 μM and 100 μM,

201

respectively), while increased HDL-C (0.0540±0.0076, 0.0798±0.0226,

202

0.1050±0.0106 mmol/gprot at 25 μM, 50 μM and 100 μM, respectively) in

203

PA-treated HepG2 cells (Fig. 3A, 3B, 3C). These findings suggested that

204

capsiate could improve lipid metabolism in PA-treated HepG2 cells.

205

Effects of Capsiate on Glycogen Content in PA-Treated HepG2 Cells.

206

Compared with the control group, glycogen content in the 0.25 mM PA-treated

207

group was significantly decreased (0.0185±0.0020 mg/106 cells vs 0.0065±

10


Page 10 of 42

Page 11 of 42


208

0.0007 mg/106 cells, P = 0.008). And compared with the PA-alone group,

209

capsiate effectively increased glycogen content (0.0090±0.0014, 0.0110±

210

0.0018, 0.0146±0.0008 mg/106 cells at 25 μM, 50 μM and 100 μM,

211

respectively) in PA-treated HepG2 cells (Fig. 3D), which suggested that

212

capsiate promoted glycogen synthesis, supporting the hypothesis that

213

capsiate treatment improved glucose metabolism in PA-treated HepG2 cells.

214

Effects of Capsiate on the Expressions of Lipid Metabolism-Related

215

Proteins in PA-treated HepG2 Cells. To determine how capsiate improves

216

lipid metabolism, we measured the expression of CD36, phosphorylation of

217

ACC and expression of CPT1, which are essential for lipid uptake, lipogenesis

218

and β-oxidation, respectively. After treating with 0.25 mM PA, the HepG2 cells

219

showed a markedly increase in CD36 (P = 0.002) and decrease in

220

phosphorylation of ACC (P = 0.017) and expression of CPT1 (P = 0.012). The

221

treatment with capsiate further increased CD36 (P = 0.000 at 100 μM) to up

222

regulate the fatty acid translocase (Fig. 4A), but it increased the ratio of

223

phosphorylation of ACC (P = 0.034 at 100 μM) to inactivate this lipid synthesis

224

enzyme (Fig. 4B). In the meantime, capsiate caused the ascent of CPT1 (P =

225

0.013 at 100 μM), which is responsible for the β-oxidation (Fig. 4C). These

226

results indicated that capsiate improved lipid metabolism by inactivating ACC

227

as well as increasing CD36 and CPT1 in PA-treated HepG2 cells.

228 229

Effects of Capsiate on the Expressions of Glucose Metabolism-Related Proteins in PA-Treated HepG2 Cells. For further

11



230

understanding of the effects of capsiate on glucose metabolism in high fat

231

environment, we measured the expressions of glucose metabolism-related

232

proteins, such as GLUT1, GLUT2, GLUT4, GK, PEPCK and GS. In high fat

233

environment, capsiate decreased GLUT2 (P = 0.029 at 100 μM), the main

234

isoform of glucose transporters in liver, and increased GLUT1 and GLUT4 (P =

235

0.001 and 0.029 at 100 μM, respectively), which are responsible for promoting

236

the diffusion of glucose (Fig. 5A, 5B, 5C). Meanwhile, the treatment with

237

capsiate increased GK level (P = 0.000 at 100 μM) to activate this glycolysis

238

rate-limiting enzyme, as well as decreased PEPCK level (P = 0.001 at 100 μM)

239

to inactivate this gluconeogenesis rate-limiting enzyme (Fig. 5D, 5E). However,

240

the intervention of capsiate also resulted in an increase of phosphorylation of

241

GS (P = 0.045 at 100 μM) to inactivate the enzyme for glycogen synthesis (Fig.

242

5F). Taken together, these results indicated that capsiate regulated glucose

243

metabolism by altering levels of GLUT1, GLUT2, GLUT4, GK, PEPCK as well

244

as phosphorylation of GS in PA-treated HepG2 cells.

245

Effects of Capsiate on the Expressions of Key Metabolic Regulators

246

in HepG2 Cells. AMPK, an upstream kinase of ACC, CPT1, GLUT4, GK and

247

PEPCK, is an important sensor in energy metabolism. SIRT1 also plays a

248

major role in regulating energy metabolism and partially involved in the AMPK

249

signaling pathway. To further investigate the mechanism by capsiate exerted

250

its metabolic regulatory activity, the phosphorylation status of AMPK and the

251

level of SIRT1 in HepG2 cells were examined. We found that capsiate

12


Page 12 of 42

Page 13 of 42


252

effectively increased the phosphorylation of AMPKα (P = 0.001 at 100 μM) and

253

the level of SIRT1 (P = 0.000 at 100 μM) in PA-treated HepG2 cells (Fig. 6A,

254

6B), indicating that capsiate might improve energy metabolism via the

255

activation of AMPK/SIRT1 pathway.

256

We also measured the phosphorylation of AMPKα and the level of SIRT1

257

in PA-free HepG2 cells with or without 100 μM capsiate. We found that

258

capsiate could significantly increase the phosphorylation of AMPKα (P = 0.018)

259

and the expression of SIRT1 (P = 0.006) in HepG2 cells even in PA-free

260

environment (Fig. 6C, 6D). These results suggested that capsiate activated

261

AMPK/SIRT1 signaling pathway in a PA-independent manner.

262

Moreover, FGF21 has attracted significant attention as a novel metabolic

263

regulator recently, so we also assessed the FGF21 level in HepG2 cells.

264

Interestingly, FGF21 was significantly increased (P = 0.002 at 100 μM) in

265

HepG2 cells by 0.25 mM PA and was decreased (P = 0.003 at 100 μM) after

266

treating with capsiate (Fig. 6E). This phenomenon perhaps due to a

267

self-regulation of liver caused by changes in lipid and glucose metabolism

268

status20 .

269

Effects of Compound C on Capsiate-Treated HepG2 Cells in High Fat

270

Environment. To confirm whether the effects of capsiate on lipid and glucose

271

metabolism are mediated by AMPK activation, compound C, a specific inhibitor

272

of AMPK, was used. Compared with the PA + capsiate group,

273

capsiate-induced decreases of lipid droplets, TG and TC contents in HepG2

13



274

cells were abolished (0.0571±0.0073 mmol/gprot vs 0.1197±0.0051

275

mmol/gprot, P = 0.000 and 0.0476±0.0051 mmol/gprot vs 0.0911±0.0070

276

mmol/gprot, P = 0.000, respectively) by pre-treatment with compound C (Fig.

277

7A, 7B). In addition, compared with the PA + capsiate group, capsiate-induced

278

increase of glycogen content was decreased (0.0078±0.0002 mg/106 cells vs

279

0.0010±0.0004 mg/106 cells, P = 0.000) with compound C (Fig. 7C).

280

Meanwhile, the phosphorylation of AMPKα and the expression of SIRT1 in

281

PA-treated HepG2 cells incubated with capsiate in the presence of compound

282

C were significantly decreased (P = 0.000 and 0.001, respectively), and the

283

expression of FGF21 was increased (P = 0.048) (Fig. 7D). Furthermore, the

284

increases of phosphorylation of ACC, GLUT1, GLUT4, GK and

285

phosphorylation of GS induced by capsiate in PA-treated HepG2 cells were all

286

reversed (P = 0.002, 0.000, 0.011, 0.001 and 0.000, respectively) in the

287

presence of compound C. However, pre-treatment with compound C did not

288

affect capsiate-induced increase of CD36 (P = 0.621) and decreases of

289

GLUT2 (P = 0.409) in HepG2 cells in high fat environment, and it even further

290

decreased PEPCK (P = 0.012) (Fig. 7E, 7F). Taken together, these above

291

results indicated that capsiate improved lipid and glucose metabolism in

292

PA-treated HepG2 cells at least partly via activation of AMPK.

293

DISCUSSION

14


Page 14 of 42

Page 15 of 42

294


In our current in vitro study, the important findings were that capsiate

295

could reduce lipid accumulation, decrease TG and TC, increase HDL-C and

296

glycogen of HepG2 cells in high fat environment. These significant effects of

297

capsiate were mediated by the increases of CD36, phosphorylation of ACC,

298

CPT1, GLUT1, GLUT4, GK, phosphorylation of GS, as well as by the

299

decreases of PEPCK in PA-treated HepG2 cells. With further study on the

300

mechanism of capsiate, we focused on AMPK and SIRT1, both of which were

301

energy regulating factors in hepatic cells 14, 15. The novelty of our study was that

302

we elucidated that capsiate regulated energy metabolic homeostasis via

303

activation of AMPK/SIRT1 signal pathway.

304

Liver is one of the primary tissues of energy metabolism. Obese

305

associated high fat environment always leads to metabolic disorders in liver,

306

such as abnormal lipid accumulation, insulin resistance and glycogen

307

reduction21. Therefore, improving hepatic energy metabolism is of great

308

meaning in the treatment of obesity and obesity-related diseases. Since

309

HepG2 cells displayed many of the genotypic features of normal human

310

hepatocytes22 and were used wildly to model hepatic function in vitro 23, 24, in

311

this study, we simulated the high fat environment by treating HepG2 cells with

312

PA25. Consistent with previous studies 26, our current study showed that PA

313

could induce lipid accumulation and glycogen reduction in HepG2 cells . Herein,

314

we found that capsiate, a non-pungent compound extracted from CH-19 Sweet,

15



315

could improve both lipid metabolism and glucose metabolism in PA-treated

316

HepG2 cells.

317

Then we focused on the mechanism by which capsiate modulated energy

318

metabolism in HepG2 cells. We first evaluated the effects of capsiate on lipid

319

metabolism of HepG2 cells in high fat environments, which primarily

320

determined by the uptake and oxidation of free fatty acid and the lipid

321

synthesis. The present result was in agreement with other studies that in high

322

fat environment, expression of CD36 was increased to enhance fatty acid

323

uptake in liver27, phosphorylation of ACC and expression of CPT1 were

324

significantly decreased11, 28. Our study demonstrated that capsiate further

325

increased expression of CD36, increased phosphorylation of ACC and level of

326

CPT1 in PA-treated HepG2 cells. CD36 is a class B scavenger receptor that

327

binds lipids and enables their transport into cells followed by next steps of

328

lipids metabolisms, such as β-oxidation29. The further increase of CD36 by

329

capsiate indicated that capsiate might promote the utilization of fatty acid in

330

HepG2 cell. ACC is a key lipid synthesis enzyme that could be inactivated by

331

phosphorylation. Inactivation of ACC would reduce the synthesis of malonyl

332

coenzyme A, a CPT1 inhibitor, thereby activating the β-oxidation essential

333

enzyme CPT1, which participates in lipid oxidation and fat reduction30. By

334

regulating ACC and CPT1, capsiate inhibited lipid synthesis and promoted

335

β-oxidation to correct the lipid metabolism disorder in HepG2 cells, which was

16


Page 16 of 42

Page 17 of 42


336

validated by the inhibition of lipid accumulation, the reduction of TG and TC, as

337

well as the increase of HDL-C.

338

We next determined if capsiate improved glucose metabolism of

339

PA-treated HepG2 cells. The liver regulates glucose homeostasis mostly by

340

maintaining balance between glycogenesis and glycolysis or gluconeogenesis.

341

Glycogen is an indicator of glucose metabolism, and the increase of liver

342

glycogen accumulation could attenuate lipid and glucose metabolic disorders

343

in obese mammals31. Our study found that capsiate reversed the reduction of

344

glycogen in PA-treated HepG2 cells, which indicated that capsiate alleviated

345

the disorder of glucose metabolism. Then, we observed the protein levels of

346

key glucose transporters, GLUT1, GLUT2 and GLUT4. GLUT2 is the main

347

mediator of glucose uptake and export across the hepatocyte plasma

348

membrane, which can increase hepatic glucose output in parallel with enhance

349

gluconeogenesis in glucose metabolic disorder status32. In liver, once glucose

350

metabolism disorder arises in the obese state, GLUT2 expressions would

351

increase33, 34. We observed the reduction of GLUT2 by capsiate in high fat

352

environment, which confirmed the beneficial effect of capsiate on hepatic

353

glucose homeostasis. GLUT1 and GLUT4 are glucose transporters

354

responsible for promoting the diffusion of glucose. In our study, GLUT1 and

355

GLUT4 were up regulated by capsiate and might be the major transporters of

356

hepatic glucose uptake in high fat environment. Furthermore, the results of

357

present research suggested that capsiate facilitated glucose utilization by

17



358

raising glycolytic enzyme GK, and inhibited glucose synthesis by reducing

359

gluconeogenic enzyme PEPCK in HepG2 cells. In addition, GS is a key

360

enzyme for glycogen biosynthesis which could be inactivated by

361

phosphorylation. Of interest, we found that even though capsiate up regulated

362

the phosphorylation of GS to inactivate GS, the intracellular glycogen content

363

was increased instead of being decreased. This phenomenon indicated that

364

capsiate might promote glycogen synthesis in some other ways, such as

365

activating AMPK. Other studies have reported that although AMPK caused GS

366

phosphorylation, it was capable of stimulating glycogen synthesis35. Above

367

results forced us to think about the possible mechanism by which capsiate

368

improved hepatocyte energy metabolism was AMPK-mediated.

369

AMPK is a central switch for regulating liver energy homeostasis, and

370

activating AMPK is of great significance in the treatment of obesity and

371

obesity-related metabolic disorders13, 36. We know that this protein can be

372

activated by the phosphorylation of its α-subunit, and then promotes the

373

phosphorylation of ACC and the expressions of CPT1, GLUT1, GLUT4, GK,

374

and inhibits the expression of PEPCK, finally improves the metabolism of lipid

375

and glucose37-40. Therefore, we hypothesized that AMPK was likely to be

376

targeted by capsiate. As expected, capsiate increased the phosphorylation of

377

AMPKα in PA-treated HepG2 cells, and even under normal condition, capsiate

378

also showed the capacity on activating AMPK. These results suggested that

18


Page 18 of 42

Page 19 of 42


379

capsiate activated AMPK to regulate lipid and glucose metabolism in HepG2

380

cells.

381

Furthermore, previous studies mentioned that phosphorylation of AMPKα

382

could activate SIRT1 directly41, and with regard that SIRT1 also plays an

383

important role in the regulation of lipid and glucose metabolism 42, 43, we

384

speculated that if SIRT1 was another possible target of capsiate. Thus, we

385

detected the SIRT1 expression of HepG2 cells in this study. In line with

386

previous observation44，there was lack of change in SIRT1 whether the HepG2

387

cells were treated with PA or not. However, after treated by capsiate, the cells

388

expressed significant higher SIRT1. We therefore demonstrated for the first

389

time that, capsiate could simultaneously increase the phosphorylation of

390

AMPK and the expression of SIRT1 to improve lipid and glucose metabolism in

391

HepG2 cells.

392

In addition, FGF21, a novel metabolic stress hormone mainly secreted by

393

liver20, 45, 46, was increased in NAFLD and considered as an independent

394

predictor of fatty liver disease 47-49. The present study showed that FGF21 of

395

HepG2 cells in high fat environment were reduced by capsiate. Nevertheless,

396

some previous studies reported that the trend of FGF21 changed resembled to

397

AMPK/SIRT1, which might be due to the role of FGF21 as an upstream

398

activator to AMPK/SIRT1 for high fat environment adaptations

399

we found that the activation of AMPK/SIRT1 was increased by capsiate rather

400

than decreased with the reduction of FGF21. We assumed that the metabolic

19


50, 51

. However,


401

disorders have been attenuated by capsiate, therefore, the hepatocyte had no

402

more need for releasing FGF21 to adapt high fat environment. Further

403

research of effects of capsiate on FGF21 and metabolic disorders must be

404

compelling.

405

To further confirm whether the effects of capsiate were mediated by

406

activation of AMPK, we used compound C to inhibit AMPK. We found that

407

changes of most indexes induced by capsiate, such as phosphorylation of

408

ACC, GLUT1, GLUT4, GK and phosphorylation of GS, were reversed by

409

compound C. Furthermore, the expression of SIRT1 was also significantly

410

decreased by compound C, which partly demonstrated that SIRT1 might be

411

located downstream of AMPK. These phenomena suggested that capsiate

412

exerted its beneficial metabolic effects by the activation of AMPK/SIRT1

413

pathway in PA-treated HepG2 cells.

414

However, we also found that pre-treatment with compound C did not affect

415

capsiate-induced increase of CD36 and decrease of GLUT2, and it even

416

further reduced PEPCK in high fat environment. These phenomena suggested

417

that AMPK/SIRT1 was one of the targets of capsiate, and more work is needed

418

to distinguish the other mechanisms co-existed in the regulation of energy

419

metabolism by capsiate.

420

In conclusion, this study reported the novel finding that capsiate improved

421

cellular lipid and glucose metabolism in HepG2 cells in high fat environment,

422

which may be associated with the activation of AMPK/SIRT1 pathway. Since

20


Page 20 of 42

Page 21 of 42


423

capsiate is hydrolysed and essentially absorbed as vanillyl alcohol in vivo,

424

which held the same biological properties of capsiate52, the outcome of the

425

current study indicated an effective therapeutic approach for treatment of

426

obesity-related hepatic disease. We proposed that better understanding of

427

capsiate could open up possibilities to manipulate energy expenditure in

428

patients with obesity and obesity-related metabolic diseases by new drugs or

429

even with dietary supplementation.

430

ACKNOWLEDGMENT

431

We thank Prof. Ji-hua Chen for helpful assistance with the experiments. We

432

also thank Prof. Rui-xue Huang for valuable advice.

433

AUTHOR INFORMATION

434

Corresponding Author

435

*Phone: +8615974222668. E-mail: [email protected]. Fax: + 86 0731

436

84805454.

437

ORCID

438

Hong Qin: 0000-0002-4578-5118

439

Funding

440

This study was supported by National Natural Science Foundation of China

441

(No.81302421), Natural Science Foundation of Hunan Province (No.

21



442

2018JJ2550) and Fundamental Research Funds for the Central Universities of

443

Central South University (1053320180830).

444

Notes

445

The authors declare no competing financial interest.

446

ABBREVIATIONS USED

447

AMPK, AMP-activated protein kinase; ACC, Acetyl CoA Carboxylase; CD36,

448

cluster of differentiation 36; CPT1, carnitine palmityltransferase 1; FGF21,

449

fibroblast growth factor 21; GK, glucokinase; GLUT1, glucose transporter 1;

450

GLUT2, glucose transporter 2; GLUT4, glucose transporter 4; GS, glycogen

451

synthase; HDL-C, high-density lipoprotein cholesterol; NAFLD, non-alcoholic

452

fatty liver disease; PA, palmitic acid; PEPCK, phosphoenolpyruvate

453

carboxykinase; p-AMPK, phospho-AMP- activated protein kinase; p-ACC,

454

phospho-Acetyl-CoA Carboxylase; p-GS, phospho-glycogen synthase; SIRT1,

455

sirtuin1; TC, total cholesterol; TG, triglyceride

456

REFERENCES

457 458

(1) Lonardo, A.; Bellentani, S.; Argo, C. K.; Ballestri, S.; Byrne, C. D.; Caldwell, S. H.; Cortez-Pinto, H.; Grieco, A.; Machado, M. V.; Miele, L.; Targher, G. Epidemiological

459 460

modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups. Dig. Liver Dis. 2015, 47, 997-1006.

461 462

(2) Sumida, Y.; Yoneda, M. Current and future pharmacological therapies for NAFLD/NASH. J. Gastroenterol. 2018, 53, 362-376.

463

(3) Baghernya, M.; Nobili, V.; Blesso, C. N.; Sahebkar, A. Medicinal plants and bioactive

464 465

natural compounds in the treatment of non-alcoholic fatty liver disease: a clinical review. Pharmacol. Res. 2017, doi: 10.1016/j.phrs.2017.12.020.

22


Page 22 of 42

Page 23 of 42


466

(4) Sasahara, I.; Furuhata, Y.; Iwasaki, Y.; Inoue, N.; Sato, H.; Watanabe, T.; Takahashi, M.

467 468 469 470

Assessment of the biological similarity of three capsaicin analogs (capsinoids) found in non-pungent chili pepper (CH-19 sweet) fruits. Biosci. Biotech. Bioch. 2010, 74, 274-278. (5) Sancho, R.; Lucena, C.; Macho, A.; Calzado, M. A.; Blanco-Molina, M.; Minassi, A.; Appendino, G.; Munoz, E. Immunosuppressive activity of capsaicinoids: capsiate derived

471 472

from sweet peppers inhibits NF-kappaB activation and is a potent antiinflammatory compound in vivo. Eur. J. Immunol. 2002, 32, 1753-1763.

473 474

(6) Kwon, D. Y.; Kim, Y. S.; Ryu, S. Y.; Cha, M. R.; Yon, G. H.; Yang, H. J.; Kim, M. J.; Kang, S.; Park, S. Capsiate improves glucose metabolism by improving insulin sensitivity better

475

than capsaicin in diabetic rats. J. Nutr. Biochem. 2013, 24, 1078-1085.

476 477

(7) Saito, M.; Yoneshiro, T. Capsinoids and related food ingredients activating brown fat thermogenesis and reducing body fat in humans. Curr. Opin. Lipidol. 2013, 24, 71-77.

478 479

(8) Josse, A. R.; Sherriffs, S. S.; Holwerda, A. M.; Andrews, R.; Staples, A. W.; Phillips, S. M. Effects of capsinoid ingestion on energy expenditure and lipid oxidation at rest and

480 481

during exercise. Nutr. Metab. 2010, 7, 65. (9) Hachiya, S.; Kawabata, F.; Ohnuki, K.; Inoue, N.; Yoneda, H.; Yazawa, S.; Fushiki, T.

482

Effects of CH-19 sweet, a non-pungent cultivar of red pepper, on sympathetic nervous

483 484

activity, body temperature, heart rate, and blood pressure in humans. Biosci. Biotech. Bioch. 2007, 71, 671-676.

485 486

(10) Ohyama, K.; Nogusa, Y.; Shinoda, K.; Suzuki, K.; Bannai, M.; Kajimura, S. A synergistic antiobesity effect by a combination of capsinoids and cold temperature through

487 488 489 490

promoting beige adipocyte biogenesis. Diabetes. 2016, 65, 1410-1423.

491

increasing insulin levels and glycogen content better than capsiate in

492 493 494 495

streptozotocin-induced diabetic rats. J. Agric. Food Chem. 2017, 65, 2323-2330. (13) Hardie, D. G. AMPK: a key regulator of energy balance in the single cell and the whole organism. Int J. Obes. (Lond) . 2008, 32 Suppl 4, S7-S12. (14) Viollet, B.; Guigas, B.; Leclerc, J.; Hebrard, S.; Lantier, L.; Mounier, R.; Andreelli, F.;

496 497

Foretz, M. AMP-activated protein kinase in the regulation of hepatic energy metabolism: from physiology to therapeutic perspectives. Acta Physiol. (Oxf) . 2009, 196, 81-98.

498 499 500

(15) Li, X. SIRT1 and energy metabolism. Acta Biochim. Biophys. Sin. (Shanghai) . 2013, 45, 51-60. (16) Musso, G.; Gambino, R.; Cassader, M. Emerging molecular targets for the treatment

501 502

of nonalcoholic fatty liver disease. Annu. Rev. Med. 2010, 61, 375-392. (17) Colak, Y.; Ozturk, O.; Senates, E.; Tuncer, I.; Yorulmaz, E.; Adali, G.; Doganay, L.; Enc,

503 504

F. Y. SIRT1 as a potential therapeutic target for treatment of nonalcoholic fatty liver disease. Med Sci. Monit. 2011, 17, Y5-Y9.

505

(18) Qin, H.; Liu, Y.; Lu, N.; Li, Y.; Sun, C. H. cis-9,trans-11-Conjugated linoleic acid

506 507

activates AMP-activated protein kinase in attenuation of insulin resistance in C2C12 myotubes. J. Agric. Food Chem. 2009, 57, 4452-4458.

508 509

(19) Weston, C. J.; Shepherd, E. L.; Claridge, L. C.; Rantakari, P.; Curbishley, S. M.; Tomlinson, J. W.; Hubscher, S. G.; Reynolds, G. M.; Aalto, K.; Anstee, Q. M.; Jalkanen, S.;

(11) Qin, H.; Chen, X.; Hu, X. Y.; Yuan, Q. Capsinoids suppress fat accumulation via lipid metabolism. Mol. Med. Rep. 2015, 11, 1669-1674. (12) Zhang, S.; Ma, X.; Zhang, L.; Sun, H.; Liu, X. Capsaicin reduces blood glucose by

23



510

Salmi, M.; Smith, D. J.; Day, C. P.; Adams, D. H. Vascular adhesion protein -1 promotes

511 512 513 514

liver inflammation and drives hepatic fibrosis. J. Clin. Invest. 2015, 125, 501-520. (20) Markan, K. R.; Naber, M. C.; Ameka, M. K.; Anderegg, M. D.; Mangelsdorf, D. J.; Kliewer, S. A.; Mohammadi, M.; Potthoff, M. J. Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding. Diabetes. 2014, 63,

515 516

4057-4063. (21) Fan, J. G.; Cao, H. X. Role of diet and nutritional management in non -alcoholic fatty

517 518

liver disease. J. Gastroenterol Hepatol. 2013, 28 Suppl 4 , 81-87. (22) Donato, M. T.; Tolosa, L.; Gomez-Lechon, M. J. Culture and Functional

519

characterization of human hepatoma HepG2 Cells. Methods Mol. Biol. 2015, 1250, 77-93.

520 521

(23) Tu, Z.; Moss-Pierce, T.; Ford, P.; Jiang, T. A. Rosemary (Rosmarinus officinalis L.) extract regulates glucose and lipid metabolism by activating AMPK and PPAR pathways in

522 523

HepG2 cells. J. Agric. Food Chem. 2013, 61, 2803-2810. (24) Kim, M.; Lim, S. J.; Lee, H. J.; Kim, S. Y.; Nho, C. W. Gomisin J inhibits oleic

524 525

acid-induced hepatic lipogenesis by activation of the AMPK-dependent pathway and inhibition of the hepatokine fetuin-A in HepG2 cells. J. Agric. Food Chem. 2015, 63,

526

9729-9739.

527 528

(25) Wang, L. J.; Guan, X. Q.; Liu, L.; Tang, Y. T.; Zhu, L. R. Role of uncoupling protein-2 in insulin-resistance induced by palmic acid in HepG2 cells and its relationship to nuclear

529 530

factor-κB. Chinese Journal of Biologicals . 2010, 23, 807-812.

531 532 533 534

and lipid metabolism disorder in palmitate-induced HepG2 cells. Chinese Pharmacological Bulletin. 2011, 27, 1383-1387. (27) Ma, S.; Yang, D.; Li, D.; Tan, Y.; Tang, B.; Yang, Y. Inhibition of uncoupling protein 2 with genipin exacerbates palmitate-induced hepatic steatosis. Lipids Health Dis. 2012, 11,

535

154.

536 537 538 539

(28) Han, L.; Li, J.; Chen, Y.; Wang, W.; Zhang, D.; Liu, G. Effects of ghrelin on triglyceride accumulation and glucose uptake in primary cultured rat myoblasts under palmitic acid-induced high fat conditions. Int J. Endocrinol. 2015, 2015, 635863. (29) Holloway, G. P.; Luiken, J. J.; Glatz, J. F.; Spriet, L. L.; Bonen, A. Contribution of

540 541

FAT/CD36 to the regulation of skeletal muscle fatty acid oxidation: an overview. Acta. Physiol. (Oxf). 2008, 194, 293-309.

542 543 544

(30) Kim, M. K.; Kim, S. H.; Yu, H. S.; Park, H. G.; Kang, U. G.; Ahn, Y. M.; Kim, Y. S. The effect of clozapine on the AMPK-ACC-CPT1 pathway in the rat frontal cortex. Int. J. Neuropsychopharmacol. 2012, 15, 907-917.

545 546

(31) Lopez-Soldado, I.; Zafra, D.; Duran, J.; Adrover, A.; Calbo, J.; Guinovart, J. J. Liver glycogen reduces food intake and attenuates obesity in a high -fat diet-fed mouse model.

547 548

Diabetes. 2015, 64, 796-807.

(26) Gong, S. J.; Liu, Z. H.; Huang, J. A.; Wang, L. L.; Yang, X. H. Mechanism of glucose

(32) Weinstein, S. P.; O'Boyle, E.; Fisher, M.; Haber, R. S. Regulation of GLUT2 glucose

549

transporter expression in liver by thyroid hormone: evidence for hormonal regulation of the

550 551

hepatic glucose transport system. Endocrinology. 1994, 135, 649-654. (33) Postic, C.; Burcelin, R.; Rencurel, F.; Pegorier, J. P.; Loizeau, M.; Girard, J.; Leturque ,

552 553

A. Evidence for a transient inhibitory effect of insulin on GLUT2 expression in the liver: studies in vivo and in vitro. Biochem. J. 1993, 293 ( Pt 1) , 119-124.

24


Page 24 of 42

Page 25 of 42


554

(34) Yamamoto, T.; Fukumoto, H.; Koh, G.; Yano, H.; Yasuda, K.; Masuda, K.; Ikeda, H.;

555 556 557 558

Imura, H.; Seino, Y. Liver and muscle-fat type glucose transporter gene expression in obese and diabetic rats. Biochem. Biophys. Res. Commun. 1991, 175, 995-1002. (35) Hunter, R. W.; Treebak, J. T.; Wojtaszewski, J. F.; Sakamoto, K. Molecular mechanism by which AMP-activated protein kinase activation promotes glycogen accumulation in

559 560

muscle. Diabetes. 2011, 60, 766-774. (36) O'Neill, H. M.; Holloway, G. P.; Steinberg, G. R. AMPK regulation of fatty acid

561 562

metabolism and mitochondrial biogenesis: implications for obesity. Mol. Cell. Endocrinol. 2013, 366, 135-151.

563

(37) Ruderman, N. B.; Saha, A. K.; Kraegen, E. W. Minireview: malonyl CoA,

564 565

AMP-activated protein kinase, and adiposity. Endocrinology. 2003, 144, 5166-5171. (38) Russell, R. R.; Bergeron, R.; Shulman, G. I.; Young, L. H. Translocation of myocardial

566 567

GLUT-4 and increased glucose uptake through activation of AMPK by AICAR. Am. J. Physiol. 1999, 277, H643-H649.

568 569

(39) Polakof, S.; Panserat, S.; Craig, P. M.; Martyres, D. J.; Plagnes-Juan, E.; Savari, S.; Aris-Brosou, S.; Moon, T. W. The metabolic consequences of hepatic AMP-kinase

570

phosphorylation in rainbow trout. Plos One. 2011, 6, e20228.

571 572

(40) Wu, N.; Zheng, B.; Shaywitz, A.; Dagon, Y.; Tower, C.; Bellinger, G.; Shen, C. H.; Wen, J.; Asara, J.; McGraw, T. E.; Kahn, B. B.; Cantley, L. C. AMPK-dependent

573 574

degradation of TXNIP upon energy stress leads to enhanced glucose uptake via GLUT1. Mol. Cell. 2013, 49, 1167-1175.

575 576 577 578

(41) Baskaran, P.; Krishnan, V.; Ren, J.; Thyagarajan, B. Capsaicin induces browning of white adipose tissue and counters obesity by activating TRPV1 channel-dependent mechanisms. Br. J. Pharmacol. 2016, 173, 2369-2389. (42) Hou, X.; Xu, S.; Maitland-Toolan, K. A.; Sato, K.; Jiang, B.; Ido, Y.; Lan, F.; Walsh, K.;

579

Wierzbicki, M.; Verbeuren, T. J.; Cohen, R. A.; Zang, M. SIRT1 regulates hepatocyte lipid

580 581 582 583

metabolism through activating AMP-activated protein kinase. J. Biol. Chem. 2008, 283, 20015-20026. (43) Banerjee, J.; Bruckbauer, A.; Zemel, M. B. Activation of the AMPK/Sirt1 pathway by a leucine-metformin combination increases insulin sensitivity in skeletal muscle, and

584 585

stimulates glucose and lipid metabolism and increases life span in Caenorhabditis elegans. Metabolism. 2016, 65, 1679-1691.

586 587 588

(44) Pang, J.; Dai, Y.; Zhang, T. M. The modulation of SIRT1 expression by different types of high fat state in hepatocytes. Progress in Modern Biomedicine . 2013, 3205-3208. (45) Seo, J. A.; Kim, N. H. Fibroblast growth factor 21: a novel metabolic regulator.

589 590

Diabetes Metab. J. 2012, 36, 26-28.

591 592

Adaptation and the Treatment of Metabolic Diseases. Diabetes Metab. J. 2014, 38, 245-251.

(46) Kim, K. H.; Lee, M. S. FGF21 as a Stress Hormone: The Roles of FGF21 in Stress

593

(47) Liu, W. Y.; Huang, S.; Shi, K. Q.; Zhao, C. C.; Chen, L. L.; Braddock, M.; Chen, Y. P.;

594 595

Feng, W. K.; Zheng, M. H. The role of fibroblast growth factor 21 in the pathogenesis of liver disease: a novel predictor and therapeutic target. Expert Opin. Ther. Targets. 2014, 18,

596

1305-1313.

25



597

(48) Li, H.; Fang, Q.; Gao, F.; Fan, J.; Zhou, J.; Wang, X.; Zhang, H.; Pan, X.; Bao, Y.;

598 599 600 601

Xiang, K.; Xu, A.; Jia, W. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J. Hepatol. 2010, 53, 934-940. (49) Li, H.; Dong, K.; Fang, Q.; Hou, X.; Zhou, M.; Bao, Y.; Xiang, K.; Xu, A.; Jia, W. High

602 603

serum level of fibroblast growth factor 21 is an independent predictor of non-alcoholic fatty liver disease: a 3-year prospective study in China. J. Hepatol. 2013, 58, 557-563.

604 605

(50) Canto, C.; Auwerx, J. Cell biology. FGF21 takes a fat bite. Science. 2012, 336, 675-676.

606

(51) Zhu, S.; Ma, L.; Wu, Y.; Ye, X.; Zhang, T.; Zhang, Q.; Rasoul, L. M.; Liu, Y.; Guo, M.;

607 608

Zhou, B.; Ren, G.; Li, D. FGF21 treatment ameliorates alcoholic fatty liver through activation of AMPK-SIRT1 pathway. Acta Biochim. Biophys. Sin. (Shanghai) . 2014, 46,

609 610

1041-1048. (52) Rosa, A.; Atzeri, A.; Deiana, M.; Melis, M. P.; Incani, A.; Corona, G.; Loru, D.;

611 612

Appendino, G.; Dessi, M. A. Protective effect of vanilloids against tert-butyl hydroperoxide-induced oxidative stress in vero cells culture. J Agric. Food Chem. 2008,

613

56, 3546-3553.

614

Figure captions

615

Figure 1. Effects of PA and capsiate on HepG2 cell viability. (A) HepG2 cells

616

were treated with different concentrations of PA (0, 0.125, 0.25, 0.5 and 1.0

617

mM) for 48 h. (B) HepG2 cells were treated with different concentrations of

618

capsiate (0, 12.5, 25, 50, 100, 200 and 400 μM) for 24 h. (C) HepG2 cells were

619

treated with 0.25 mM PA for 24h and then co-incubated with different

620

concentrations of capsiate (0, 12.5, 25, 50, 100, 200 and 400 μM) for an

621

additional 24 h. Data are presented as mean ± SD and analyzed with

622

one-way ANOVA (n = 3). (*) P < 0.05 versus the control group.

623

Figure 2. Effects of capsiate on lipid accumulation in PA-treated HepG2 cells.

624

All groups were stained with Oil red O to observe lipid droplets at 400×

625

magnification. Scale bar=50 μm. (A) HepG2 cells were cultured in the absence 26


Page 26 of 42

Page 27 of 42


626

of PA and capsiate; (B) HepG2 cells were treated with 0.25 mM PA for 48 h; (C

627

- E) HepG2 cells were treated with 0.25 mM PA for 24 h, then the cells which

628

exposed to PA were treated with (C) 25 μM capsiate, (D) 50 μM capsiate or (E)

629

100 μM capsiate for 24 h.

630

Figure 3. Effects of capsiate on TG, TC, HDL-C and glycogen contents in

631

PA-treated HepG2 cells. HepG2 cells were treated with or without 0.25 mM PA

632

for 24 h. Then the cells which exposed to PA were treated with capsiate (0, 25,

633

50, and 100 μM) for 24 h. (A) TG, (B) TC, (C) HDL-C levels of each group were

634

assayed and expressed in the bar chart. (D) Glycogen content of each group

635

was assayed and expressed in the bar chart. Data are presented as mean ±

636

SD and analyzed with one-way ANOVA (n = 3). (a) P < 0.05 versus the control

637

group; (b) P < 0.05 versus the PA-alone group.

638

Figure 4. Effects of capsiate on the expressions of lipid metabolism-related

639

proteins in PA-treated HepG2 cells. HepG2 cells were treated with or without

640

0.25 mM PA for 24 h. Then the cells which exposed to PA were treated with

641

capsiate (0, 25, 50, and 100 μM) for 24 h. (A) Protein expression of CD36, (B)

642

phosphorylation of ACC and (C) expression of CPT1A were quantified by

643

densitometry, and the relative intensities are expressed in the bar chart. Data

644

are presented as mean ± SD and analyzed with one-way ANOVA (n = 3). (a)

645

P < 0.05 versus the control group; (b) P < 0.05 versus the PA-alone group.

27



646

Figure 5. Effects of capsiate on the expressions of glucose

647

metabolism-related proteins in PA-treated HepG2 cells. HepG2 cells were

648

treated with or without 0.25 mM PA for 24 h. Then the cells which exposed to

649

PA were treated with capsiate (0, 25, 50, and 100 μM) for 24 h. Protein

650

expressions of (A) GLUT1, (B) GLUT2, (C) GLUT4, (D) GK, (E) PEPCK, (F)

651

GS and phosphorylation of GS were quantified by densitometry, and the

652

relative intensities are expressed in the bar chart. Data are presented as mean

653

± SD and analyzed with one-way ANOVA (n = 3). (a) P < 0.05 versus the

654

control group; (b) P < 0.05 versus the PA-alone group.

655

Figure 6. Effects of capsiate on the expressions of key metabolic regulators in

656

HepG2 cells. (A, B, E) HepG2 cells were treated with or without 0.25 mM PA

657

for 24 h, then the cells which exposed to PA were treated with capsiate (0, 25,

658

50, and 100 μM) for 24 h. (A) Protein expression of AMPKα, phosphorylation of

659

AMPKα, expressions of (B) SIRT1 and (E) FGF21 were quantified by

660

densitometry, and the relative intensities are expressed in the bar chart. Data

661

are presented as mean ± SD and analyzed with one-way ANOVA. (a) P

Improvement of Lipid and Glucose Metabolism by Capsiate in Palmitic

Recommend Documents